Advisors Asset Management Inc. Purchases 117,851 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Advisors Asset Management Inc. significantly increased its stake in Recursion Pharmaceuticals by 753.8%, acquiring a total of 133,485 shares valued at approximately $706,000.
• Recursion Pharmaceuticals reported a quarterly revenue of $19.10 million, exceeding expectations, but posted earnings of (-$0.41) per share, missing the consensus estimate.
• Analysts' ratings for Recursion Pharmaceuticals include two "Buy" ratings and three "Hold" ratings, with a consensus target price of $7.25 per share.

Advisors Asset Management Inc. boosted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 753.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,485 shares of the company's stock after acquiring an additional 117,851 shares during the period. Advisors Asset Management Inc.'s holdings in Recursion Pharmaceuticals were worth $706,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Ensign Peak Advisors Inc lifted its position in Recursion Pharmaceuticals by 0.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after acquiring an additional 1,300 shares during the last quarter. Clear Creek Financial Management LLC raised its position in shares of Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after buying an additional 1,907 shares during the last quarter. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares in the last quarter. QRG Capital Management Inc. grew its position in Recursion Pharmaceuticals by 8.5% during the first quarter. QRG Capital Management Inc. now owns 28,515 shares of the company's stock worth $151,000 after buying an additional 2,244 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Recursion Pharmaceuticals by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,864 shares of the company's stock valued at $163,000 after acquiring an additional 2,587 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.02 on Friday, reaching $4.83. The company's stock had a trading volume of 17,070,681 shares, compared to its average volume of 15,440,485. The firm has a market cap of $2.10 billion, a PE ratio of -2.71 and a beta of 0.91. The business has a 50-day moving average price of $5.34 and a 200 day moving average price of $5.30. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The business's revenue was up 33.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.40) EPS. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on RXRX. Needham & Company LLC restated a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target on the stock. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $7.25.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider directly owned 668,197 shares of the company's stock, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.43% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.